HER2 Support Group Forums - View Single Post - To Al , Joe , or anyone with info on Avastin trial

Joe · 01-31-2006, 04:31 PM

Avastin (bevacizumab) and Herceptin (Trastuzumab) have only completed phase I clinical trials. Dr. Mark Pegram of the Jonnson Cancer Center is currently conducting phase II trials of the combination.

I managed to "Google" the following:

Trials combining bevacizumab and trastuzumab
When we launched E2100, literally no data existed concerning the use of combination monoclonal antibody therapy in patients with breast cancer for any antibody, let alone bevacizumab and trastuzumab. Since that time, Mark Pegram and his colleagues at UCLA, based on some wonderful preclinical work, combined bevacizumab and trastuzumab in a Phase I trial that was recently reported (Pegram 2004), and they now have an ongoing Phase II trial.

The Phase I trial enrolled a total of nine patients because the combination was fairly nontoxic, and the trial zipped through the dose levels. Five of the nine patients receiving bevacizumab and trastuzumab had an objective response, and other patients had prolonged stabilization of their disease (Pegram 2004). You don’t want to make too much of a Phase I trial or a trial with nine patients, but for a treatment with no chemotherapy involved, this is a respectable response rate. If bevacizumab plus trastuzumab plays out in the larger Phase II trial, it will be a felicitous combination.

01-31-2006, 04:31 PM	#3
Joe Webmaster Join Date: Feb 2005 Location: Home of the "Flying Tomato" Carlsbad, CA Posts: 2,036	Avastin (bevacizumab) and Herceptin (Trastuzumab) have only completed phase I clinical trials. Dr. Mark Pegram of the Jonnson Cancer Center is currently conducting phase II trials of the combination. I managed to "Google" the following: Trials combining bevacizumab and trastuzumab When we launched E2100, literally no data existed concerning the use of combination monoclonal antibody therapy in patients with breast cancer for any antibody, let alone bevacizumab and trastuzumab. Since that time, Mark Pegram and his colleagues at UCLA, based on some wonderful preclinical work, combined bevacizumab and trastuzumab in a Phase I trial that was recently reported (Pegram 2004), and they now have an ongoing Phase II trial. The Phase I trial enrolled a total of nine patients because the combination was fairly nontoxic, and the trial zipped through the dose levels. Five of the nine patients receiving bevacizumab and trastuzumab had an objective response, and other patients had prolonged stabilization of their disease (Pegram 2004). You don’t want to make too much of a Phase I trial or a trial with nine patients, but for a treatment with no chemotherapy involved, this is a respectable response rate. If bevacizumab plus trastuzumab plays out in the larger Phase II trial, it will be a felicitous combination.